FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations

The FDA announced on October 29, 2026 that it has updated the framework that governs how it evaluates and inspects human drug manufacturing facilities.¹ The revised document, Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations (ConOps 2.0),² took effect October 21, 2026, and was posted October 29. It replaces the original version from June 2017.

ConOps 2.0 is an agreement between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). The agreement sets out how the 2 offices coordinate marketing application assessments, inspections, and related compliance work. It covers preapproval, postapproval, surveillance, and for-cause inspections. The FDA says the update is meant to help the agency manage the growing complexity of pharmaceutical manufacturing.

What Has Changed?

The following 4 main items have changed:

• Reorganization alignment. The document now reflects the FDA’s October 2024 reorganization, in which the field-based Office of Regulatory Affairs became OII.
• Remote regulatory assessments (RRAs). RRAs are now formally recognized as a tool for evaluating facilities.
• Mutual recognition agreement (MRA) inspection reports. Inspection reports from trusted foreign regulators can now be used as evaluation inputs.
• Clarified roles. CDER and OII responsibilities are redefined across all 4 inspection types.

The agency also listed 5 objectives. The first is to apply a risk-based approach that makes facility evaluations, inspections, and regulatory decisions consistent, efficient, and transparent. The others are to align CDER and OII functional units, to improve capacity by reducing duplicated effort, to improve the quality of facility information and access to it across FDA, and to meet user fee commitments while shortening regulatory timelines.

What the Change Means for Manufacturers

The FDA relied heavily on RRAs during the COVID-19 pandemic. Writing them into the ConOps makes them a standard part of how sites are evaluated, not a stopgap. Manufacturers should expect records requests and possibly virtual walkthroughs as part of application assessments and surveillance. A firm that can produce organized, complete documentation quickly may be in a better position. A firm that can’t may be more likely to face follow-up or an on-site visit.

Because MRA inspection reports now formally count, how a site performs during an inspection by a partner authority, such as one in the European Union, can directly shape FDA’s view of that site. Companies with global networks should treat every MRA-partner inspection as an FDA-relevant event. That means tracking findings, corrective actions, and closure status across regulators, not just for the FDA.

The 2017 framework created integrated teams that paired CDER reviewers with field investigators. Version 2.0 clarifies roles and targets duplicated effort, which could reduce redundant information requests and help the FDA meet user fee goal dates under Prescription Drug User Fee Act, Generic Drug User Fee Amendments, and Biosimilar User Fee Amendments. The FDA has not published new performance figures, so the real effect on review times remains to be seen.

The ConOps puts risk-based decision-making at the center. A facility’s compliance history, the quality of its application data, and its overall risk profile will continue to determine whether the FDA inspects, assesses remotely, or relies on other evidence. Data integrity and an accurate site dossier are still the strongest levers manufacturers control.

What Are the Next Steps?

Quality and regulatory affairs teams should review the full ConOps and check internal inspection-readiness programs against all 4 inspection types. Standard operating procedures should be updated for responding to RRAs. Tracking of inspections by FDA and MRA partners should be consolidated. And manufacturers should make sure contract manufacturing partners are held to the same readiness expectations.

The FDA’s announcement did not include statements from agency officials or changes to specific classification or reporting timelines. Manufacturers should check the full document for procedural details.

References

1. Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations. FDA.gov. October 29, 2026. Accessed October 30, 2026. https://www.fda.gov/drugs/pharmaceutical-quality-resources/integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept-operations
2. CDER and OII. Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations. FDA.gov. Accessed October 30, 2026. https://www.fda.gov/media/107225/download?attachment